Sotomi, Y., Kozuma, K., Higuchi, Y., Nakazawa, G., Morino, Y., Ando, K., . . . Tanabe, Y. (2026). 1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): A multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial. Lancet, 408(10553), 440-453.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
Sotomi, Yohei, et al. "1-month Versus 12-month Dual Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation (OPTIMA-AF): A Multicentre, Open-label, Hybrid Non-inferiority and Superiority, Randomised, Controlled Trial."
Lancet 408, no. 10553 (2026): 440-453.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
Sotomi, Yohei, et al. "1-month Versus 12-month Dual Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation (OPTIMA-AF): A Multicentre, Open-label, Hybrid Non-inferiority and Superiority, Randomised, Controlled Trial."
Lancet, vol. 408, no. 10553, 2026, pp. 440-453.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.